Anatabine

Drug Profile

Anatabine

Alternative Names: Anatabine citrate; Controlled release; RCP-006

Latest Information Update: 28 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Star Scientific
  • Developer Rock Creek Pharmaceuticals Inc; Roskamp Institute; Zenith Technology Corporation
  • Class Alkaloids; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Cholinergic receptor agonists; Glycogen synthase kinase 3 beta inhibitors; NF-kappa B inhibitors; STAT3 transcription factor inhibitors; STAT3 transcription factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Preclinical Psoriasis
  • No development reported Brain injuries; Cognition disorders; Inflammation; Multiple sclerosis; Neurological disorders; Osteoarthritis; Smoking withdrawal; Thyroiditis; Ulcerative colitis

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for preclinical development in Osteoarthritis in USA (PO)
  • 28 Oct 2018 No recent reports of development identified for preclinical development in Smoking-withdrawal in USA (PO)
  • 28 Oct 2018 No recent reports of development identified for preclinical development in Thyroiditis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top